Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 May 13;16(5):e0251801. doi: 10.1371/journal.pone.0251801

Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2

Shruti Koulgi 1,#, Vinod Jani 1,#, Mallikarjunachari Uppuladinne V N 1,#, Uddhavesh Sonavane 1, Rajendra Joshi 1,*
Editor: Chandrabose Selvaraj2
PMCID: PMC8118514  PMID: 33984041

Abstract

Drug repurposing studies targeting inhibition of RNA dependent RNA polymerase (RdRP) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have exhibited the potential effect of small molecules. In the present work a detailed interaction study between the phytochemicals from Indian medicinal plants and the RdRP of SARS-CoV-2 has been performed. The top four phytochemicals obtained through molecular docking were, swertiapuniside, cordifolide A, sitoindoside IX, and amarogentin belonging to Swertia chirayita, Tinospora cordifolia and Withania somnifera. These ligands bound to the RdRP were further studied using molecular dynamics simulations. The principal component analysis of these systems showed significant conformational changes in the finger and thumb subdomain of the RdRP. Hydrogen bonding, salt-bridge and water mediated interactions supported by MM-GBSA free energy of binding revealed strong binding of cordifolide A and sitoindoside IX to RdRP. The ligand-interacting residues belonged to either of the seven conserved motifs of the RdRP. These residues were polar and charged amino acids, namely, ARG 553, ARG 555, ASP 618, ASP 760, ASP 761, GLU 811, and SER 814. The glycosidic moieties of the phytochemicals were observed to form favourable interactions with these residues. Hence, these phytochemicals may hold the potential to act as RdRP inhibitors owing to their stability in binding to the druggable site.

Introduction

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to the current pandemic across the globe, leading to a large number of fatalities [1]. This pandemic is still ongoing and significant rise in the number of patients infected worldwide has been observed day by day. There is an immediate need to find novel preventive and therapeutic agents to combat the effect of this virus. The SARS-CoV-2, has RNA genome of around 30 K nucleotides. This genome codes for the structural, non-structural (nsp) and accessory proteins, required for the viral assembly, replication and poly-protein functioning [24]. Therefore, experimental and computational approaches towards COVID-19 therapeutics, specifically targeting these proteins have gained importance in the drug industry [5]. Researchers are trying different strategies including, testing of broad-spectrum anti-viral drugs, in-silico screening of molecular databases and rational drug design [6, 7]. These approaches have enabled identification of lead compounds against the viral proteins based on the genomic information and pathological characteristics of COVID-19 [6]. Drug repurposing is one such strategy that is also being extensively used worldwide to design drugs against this coronavirus [710]. To understand how similar is the SARS-CoV-2 in comparison to the earlier known coronaviruses, several sequence comparison studies have been performed [1117]. The phylogenetic analysis have revealed the conservation of the sequence of the coronaviruses across different species [1416]. Amongst the various potential drug targets of SARS-CoV-2, RdRP, is known to be the most conserved among the viruses [18, 19]. RdRP has been extensively studied using various drug discovery techniques for COVID-19 therapeutics [20, 21]. A range of FDA-approved RdRP inhibitors (nucleotide analogues) for previously known viral infections have been repurposed to understand their role in inihibiting SARS-CoV-2 [2228]. Several other FDA-approved drugs which are not, nucleotide analogues have also been screened against RdRP through in-silico approaches [29, 30]. These studies target towards understanding the residues involved in binding to the proposed inhibitor molecules and the mechanism of RdRP inhibition.

The three dimensional structure of the RdRP of SARS-CoV-2, resembles to that of a right cupped hand, consisting of three subdomains finger, palm and thumb [31]. The different subdomain of the RdRP of SARS-CoV-2 have been depicted in Fig 1A. The residue range of these subdomains have been shown in the Table 1. The N-terminal region of RdRP is proceeded by a nidovirus RdRp-associated nucleotidyltransferase (NiRAN) subdomain. The NiRAN and the FD subdomains are connected through the linker region. Fig 1B depicts the seven conserved motifs in the RdRP of SARS-CoV-2 and the residue range spanned by each of them. These conserved motifs flank the catalytic active site of the RdRP and hence are involved in RNA template, primer, nucleotide and inhibitor binding. The residues belonging to these functionally important sites of the RdRP have been listed in Table 1.

Fig 1. Structure of RdRP of SARS-CoV-2.

Fig 1

The different (A) subdomains and (B) the seven conserved motifs in RdRP of SARS-CoV-2 represented through color codes.

Table 1. Residue range and number for the subdomains and functionally important sites of the RdRP.

RdRP subdomains Residue Range
Finger 1 (FD1) 398–581
Finger 2 (FD2) 621–679
Palm (PD) 582–627 / 688–815
Thumb (TD) 816–919
Functionally important sites Residue name and number
Catalytic site TRP 617, CYS 622, SER 759, ASP 760, ASP 761, CYS 813
Primer binding SER 759, ASP 760, ASP 761, CYS 813, SER 814, GLN 815
Template binding LYS 500, SER 501, ASN 507
Inhibitor binding LYS 551, ARG 553, ARG 555

The available structural data of the RdRP from different viruses, was extensively analysed by Zhou Z and Bourne PE [30]. This work reported inhibitor molecules that do not belong to the class of nucleotide analogue [30]. Such studies open an avenue to explore molecules other than the nucleotide analogues as probable RdRP inhibitors. One such paradigm is the application of natural plant products as potential inhibitors against the drug target under-consideration. The glorious history of traditional medicine, involves the use of purified plant compounds in treating metabolic disorders like, diabetes and life threatening diseases like, cancer [3234]. Similar approaches have been made in order to find a plant-based compound with a potency to treat viral infections [3542]. Few of the detailed studies on use of natural compounds as inhibitors against coronaviruses drug targets, suggested that polyphenols, limonoids, and tri-terpenoids may be promising candidates [37, 38]. Earlier known in-silico and experimental studies involving phytochemicals from Indian medicinal plants, namely, Withania Somnifera, Tinospora cordifolia, Ocimum sanctum and Tinospora crispa were explored for their binding to the 3CL-protease of SARS-CoV-2 [40, 41]. Phytochemicals such as, flavonoids and structurally similar indole chalcones derivatives were investigated for their pharmokinetics and binding properties against three of SARS-CoV-2 drug targets namely, RdRP, 3CL-proteases and S-glycoprotein [42]. The availability of multiple experimental structures for the RdRP of SARS-CoV-2 along with molecular docking and simulations would enable the designing of inhibitors based on screening of phytochemicals. The present study deals with molecular docking and simulation studies of phytochemicals derived from Indian medicinal plants, with known application in treating respiratory disorders (S1 Fig in S1 File). The comparative analysis of ligand-free and phytochemical-bound RdRP was performed based on principal component analysis (PCA), molecular mechanics-generalized Born-surface area (MM-GBSA) free energy, and hydrophilic and hydrophobic contact analysis.

Methodology

Model generation

The co-ordinates for the RdRP were obtained from the SWISS-MODEL, where the template used was the cryo-EM structure with PDB ID 7BTF [43]. The model consists of 932 amino acids and two Zn+2 ions. Each Zn+2 ion is present in a tetrahedral co-ordination complex with three CYS and one HIS residues. CYS 301, 306 and 310 along with HIS 295 form the co-ordination complex with one of the Zn+2 atoms. CYS 487, 645, 646 and HIS 642 form the co-ordination complex with the other Zn+2 atom.

Phytochemical dataset

The dataset of phytochemicals was built using the protocol shown in the S1 Fig in S1 File. Initially, the information on Indian medicinal plants known to be useful in treating respiratory ailments was gathered. A total of twelve medicinal plants were selected for this study (S1 Fig in S1 File) The literature citing the medicinal use of the plants selected has been given with the S1 Fig in S1 File. The chemical structure for these phytochemicals were extracted from the PubChem and CAS databases [44, 45]. The chemical structures if obtained in any format other than three dimensional MOL2 format were subjected to conversion using OpenBabel [46]. This dataset of 150 phytochemicals was further used for molecular docking studies.

Molecular docking

The molecular docking of the phytochemical dataset was performed on the model generated for RdRP. The parameter generation was done using UCSF Chimera [47]. The AMBER14SB and generalized AMBER force field parameters were used for the RdRP and phytochemical dataset, respectively [48, 49]. The molecular docking was performed using DOCK 6 [50]. The protocol of flexible docking as reported in one of our earlier works on RdRP was followed [51]. The ligands were sorted based on the grid score, which is a measure of the effective binding of the ligand with the active site of the receptor molecule [50].

Molecular dynamics

The molecular dynamics simulations for top four phytochemicals (based on the grid score) obtained through molecular docking were performed. Table 2 shows the grid scores for the top four phytochemicals. These phytochemicals were, swertiapuniside (SWE), cordifolide A (COR), sitoindoside IX (SIT), and amarogentin (AMR) (S2 Fig in S1 File). SWE and AMR belonged to the plant Swertia chirayita, COR to Tinospora cordifolia, and SIT to Withania Somnifera. The ADMET and drug likeliness properties of these phytochemicals were calculated using two servers, admetSAR 2.0 and SwissADME [52, 53]. A detailed table and a short paragraph explaining the different parameters of absorption, distribution, metabolism and toxicity of the four phytochemicals has been given in S1 Table in S1 File. The docked complexes of these phytochemicals with RdRP were used as the start structure for the ligand-bound simulations. These ligand-bound RdRP systems have been referred as RdRP-SWE, RdRP-AMR, RdRP-SIT and RdRP-COR denoting the presence of these respective phytochemicals (Table 3). The simulations were performed using the AMBER16 simulation package [54]. The force field parameters were generated using the AMBER14SB force field for the RdRP molecule [48]. The Zinc AMBER Force Field (ZAFF) was used for parameter generation of the two Zn+2 co-ordination complexes [55]. The parameters for the phytochemicals were generated using the antechamber module of AMBERTOOLS17 and the force field used was the general atom force field [49, 56]. The docked complex was neutralized using Na+ ions followed by addition of solvent molecules. The octahedral geometry for TIP3P water model was used in order to solvate the ligand-bound RdRP systems. The molecular dynamics simulations were performed using the classical steps of minimization, temperature ramping, equilibration and production run. The minimization was performed using steepest descent followed by conjugate gradient method for a cumulative of 10000 steps. Initially, the solvent was minimized followed by the solute. The entire simulation system was gradually heated up to 300 K using the Brendensen thermostat and Langevin dynamics. The hydrogen constraints were treated using the SHAKE algorithm. After achieving the desired temperature, an equilibration was performed at constant temperature of 300 K and a constant pressure of 1 atm for 2 ns. This was followed by the production run of 50 ns. Two replicates of 50 ns were simulated. This protocol was followed for all the four ligand-bound RdRP systems. Hence, for each of the four ligand-bound RdRP systems a cumulative of 100 ns simulation data was achieved. The simulation data for the ligand-free RdRP (RdRP-APO) system were obtained from the previously reported work by the authors of this article [51]. A cumulative of 250 ns simulation data for the RdRP-APO system was used for comparative study against the RdRP systems bound to phytochemicals.

Table 2. Grid scores for the top-ranked four phytochemicals obtained through DOCK 6.

Rank Phytochemical Name Grid Score (kcal/mole)
1 Swertiapuniside (PubChem CID:5487497) -59.42
2 Cordiofolide A (PubChem CID: 102451916) -55.14
3 Sitoindoside IX (PubChem CID: 189586) -53.92
4 Amarogentin (PubChem CID: 115149) -53.39

Table 3. Information about the simulations and abbreviation used.

Simulation System Simulation length Abbreviation used
RdRP without any ligand 50 ns (5 replicates) ≈ 50 x 5 = 250 ns RdRP-APO
RdRP + Swertiapuniside 50 ns (2 replicates) ≈ 50 x 2 = 100 ns RdRP-SWE
RdRP + Amarogentin 50 ns (2 replicates) ≈ 50 x 2 = 100 ns RdRP-AMR
RdRP + Sitoindoside IX 50 ns (2 replicates) ≈ 50 x 2 = 100 ns RdRP-SIT
RdRP + Cordifolide A 50 ns (2 replicates) ≈ 50 x 2 = 100 ns RdRP-COR
Ligand name Abbreviation used in manuscript
Swertiapuniside SWE
Amarogentin AMR
Sitoindoside IX SIT
Cordifolide A COR

Analysis performed

The principal component analysis (PCA) and water mediated interaction analysis between the ligands and RdRP was performed using the cpptraj module of AMBERTOOLS17 [57]. The fluctuations were visualized using the Normal Mode Wizard (NMWiz) plugin of Visual Molecular Dynamics (VMD) [58, 59]. The GetContacts module of FlarePlot was used for calculating and visualizing the hydrogen bonding and salt bridge interactions between the ligand and RdRP molecules [60]. The MMPBSA.py module of AMBERTOOLS17 was used for calculating the free energy of binding between the ligand molecules and the RdRP [61]. The equation given below was used for calculating the free energy of binding (ΔΔGbind) between the RdRP protein and the bound phytochemical,

ΔΔGbind=ΔGcomplex(ΔGreceptor+ΔGligand)
ΔGcomplex/receptor/ligand=ΔHcomplex/receptor/ligandTΔScomplex/receptor/ligand

where, ΔGcomplex, ΔGreceptor, and ΔGligand stands for the free energy of the RdRP-Phytochemical complex, the RdRP protein and the bound phytochemical respectively. The enthalpy component, ΔHcomplex/receptor/ligand, of the free energy was considered for the calculations.

Results and discussion

Dominant subdomain level motions of RdRP

The conformational dynamics undergone by RdRP in the absence and presence of ligand was estimated by performing PCA on the non-hydrogen atoms of the RdRP residues for all the simulated systems. PCA enables the understanding of the dominant motions that lead to the conformational variation in the protein. Fig 2A–2D shows the distribution of RdRP conformers along PC 1 (black), PC 2 (red), and PC 3 (green) for RdRP-SWE, RdRP-AMR, RdRP-SIT and RdRP-COR respectively. The dotted line in Fig 2A represents the distribution of conformers for the RdRP-APO system. The PC 1 distribution for all the phytochemicals-bound RdRP systems showed the presence of two populations in comparison to the RdRP-APO. This infers that in the presence of phytochemicals the RdRP tends to explore different conformational zones. However, RdRP-APO system was observed to have a single dominant population. The distribution along PC 2 showed the occurrence of more than one population for the RdRP-APO (Fig 2A, dotted line), RdRP-SWE (Fig 2A) and RdRP-AMR (Fig 2B) systems. The RdRP-SIT and RdRP-COR systems showed a single population along PC 2. The basis of PCA suggests decrease in variance with increase in number of principal components. Hence, observing more than one population in PC 2 suggests that the conformations captured under this distribution may have occurred for a short duration within the simulation. Similarly for PC 3, multiple populations were observed but their size was comparatively lower than the first two PCs. The root mean square fluctuation (RMSF) was calculated for every residue along the first three principal components and has been given in S3 Fig in S1 File. RdRP-SWE and RdRP-SIT systems showed fluctuation in the N-terminal region which was captured by PC1. It was observed that the fluctuations in the FD1 and TD subdomain were quite significant in each of the phytochemical-bound system. To further understand what were these conformations sampled by the first three PCs the distance between FD1 and thumb subdomain were calculated. The reason behind selecting this parameter was one of the previously reported studies by Appleby and co-workers [62]. This study suggested the opening and closing of the template entry site flanked by these two domains [62].

Fig 2. PCA distribution of RdRP conformers.

Fig 2

Normalized population of conformers along principal component 1 (black), 2 (red), and 3 (green) for (A) RdRP-SWE, (B) RdRP-AMR, (C) RdRP-SIT, and (D) RdRP-COR systems. The dotted line in sub figure A is for the RdRP-APO system.

Fig 3A–3C shows the distance between the FD1 and TD subdomain captured by PC 1, 2 and 3 for all the RdRP systems, respectively. The variation in PCs throughout the simulation was captured within 51 snapshots by the cpptraj module of AMBERTOOLS17. Hence, the X-axis shows maximum 51 number of frames/snapshots. The dotted line represents the distance (28.12 Å) between FD1 and TD subdomains for the experimental structure of the apo RdRP of SARS-CoV-2 (PDB ID 7BV1) [31]. These distances greater and less than 28.12 Å suggests open and closed conformation of the template entry site, respectively. RdRP-APO (black) system was observed to have this distance close to the one seen in the experimental structure 7BV1 in the first three PCs. RdRP-SWE (red) system showed the transition from open to closed conformation of the template entry site in case of PC1 and PC3. However, in case of PC2 it was observed to be stable in the closed conformation. RdRP-AMR (green) system showed the transition from open to closed conformation in case of the first three PCs. RdRP-SIT and RdRP-COR showed the transition from closed to open conformation in case of PC1. However, the next two PCs witnessed open to closed transition similar to that observed for RdRP-SWE and RdRP-AMR. These structural changes in RdRP significantly occurred in the presence of SWE, AMR, SIT and COR. Similar observations were reported by Moustafa et al. and Thompson et al., wherein the role of finger and thumb subdomains was highlighted [63, 64]. Thus, it may be inferred that the structural changes in these two subdomains may be resultant of the binding of these phytochemicals. Hence, the molecular interactions between the phytochemicals and the RdRP residues were further investigated.

Fig 3. Open and closed conformations of RdRP.

Fig 3

Distance between the finger subdomain 1 and thumb subdomain captured by principal component (A) 1, (B) 2 and (C) 3 in case of the five RdRP systems.

Molecular interactions between phytochemicals and RdRP

The molecular interactions between the phytochemicals and RdRP residues were quantified by calculating the number of hydrogen bonds, salt bridges and water-mediated bonds formed between the two (Fig 4). Fig 4 shows the contact frequency of the interactions formed by the ligand. The interactions with contact frequency more than 0.2 have been plotted. The X-axis mentions the name of the residues with the motif/subdomain they belong to in parentheses. The average hydrogen bond distance between these residues and atoms of the ligands have been given in S2 Table in S1 File.

Fig 4. Stable interactions formed by the phytochemicals.

Fig 4

Contact frequency of the hydrogen-bond and water mediated interactions between the RdRP residues and (A) SWE, (B) AMR, (C) SIT and (D) COR.

Residues from the conserved motifs A, C, E and F were observed to be forming interactions with SWE (Fig 4A). The three residues of conserved motif C were SER 759, ASP 760, and ASP 761 which are known to form one of the catalytic sites (SDD) of RdRP. ASP 760 was observed to be involved in water mediated interactions also. ASP 618 from the motif A was observed to strongly interact with SWE through direct and water mediated hydrogen bonding. GLU 811 and SER 814 from the motif E were involved in interacting with SWE with the former one forming water mediated interactions too. LYS 551, ARG 553 and ARG 555 from the ligand binding motif F interacted with SWE, ARG 553 was also involved in the water mediated hydrogen bonding. Among all these interacting residues SER 759, ASP 760, ASP 761, SER 814 are known to be involved in primer binding [31]. LYS 798 from the palm domain was also observed to interact with SWE.

Fig 4B depicts the interactions formed by AMR. LYS 621 from motif A was observed to form the strongest interaction. This was followed by ARG 553, ASP 452 and ARG 555. ARG 553 and ARG 555 belong to the ligand binding motif F. ASP 452 which belongs to the FD1 subdomain was involved in formation of water mediated interactions. ASP 618 and ASP 760 from motifs A and C respectively, were observed to be involved in forming strong water mediated hydrogen bonds. Among all these residues ASP 760 is part of the catalytic site SDD of motif C and is also known to be involved in primer binding.

Fig 4C shows the interaction between SIT and the residues of RdRP. The residues involved were ARG 555, ASP 684, SER 682, ALA 550, SER 549, GLY 683 and ALA 558. ARG 555 was also involved in formation of water mediated interactions with SIT. SER 682, GLY 683 and ASP 684 from the motif B are known to be involved in binding to the RNA template. SER 549 and ALA 550 belong to the motif F and known to be involved in inhibitor binding. ALA 558 is part of the FD1 subdomain and plays a role in binding to the template.

Fig 4D shows the interactions formed between COR and the residues of RdRP. TRP 800, LYS 798 and HIE 810 from the PD subdomain were observed to strongly interact with COR. LYS 798 was also involved in formation of water mediated interactions. HIE 810 is one of the crucial residues of the catalytic site. GLY 616 and ASP 618 belonged to motif A. ASP 761 was observed to form water mediated interactions, and is known to be involved in primer binding and also a part of the catalytic residues. GLU 811 and SER 814 are from the motif E, GLU 811 formed water mediated interactions. SER 814 is also known to be involved in primer binding. ARG 553 and ARG 555 from the ligand binding motif F were involved in forming strong interactions with COR.

The aspartate and serine residues from the catalytic triads SDD and CSQ, respectively, were observed to form non-bonded interactions with either of the four phytochemicals. Both of these catalytic triads are also known to be involved in primer binding [31]. One of the interesting findings was involvement of stable water assisted interactions between the phytochemicals and RdRP residues from the catalytic sites. ARG 555 from motif F which is known to interact with RdRP inhibitors was observed to interact with all the four phytochemicals. SIT and COR were observed to interact with residues from the PD1 subdomain which are known to be important in binding to the RNA template. The ranking of the four phytochemicals in decreasing order of number of interactions formed was COR and SWE followed by SIT, and AMR.

Binding efficiency of phytochemicals

The thermodynamic estimation of the interactions between the phytochemicals and RdRP residues was done by calculating the MM-GBSA free energy of binding between the two [61]. S4 Fig in S1 File shows the histogram plot for the distribution of conformers along the free energy of binding between the phytochemical and the RdRP protein. All the phytochemicals except for AMR showed free energy values ranging within -10 to -50 kcal/mol. Based on this distribution of histograms an optimal average of the free energy of binding (OptimalAvgFE) was calculated using the equation given below,

OptimalAvgFE=i=1nEiPiPT

Where, n is the total number of bins calculated, Ei is the free energy value at which the bin i is calculated, Pi is the size of the population for the bin i and PT is the size of the total population under consideration.

Fig 5 shows the OptimalAvgFE values between the phytochemicals SWE (black), AMR (red), SIT (green), COR (blue) and the RdRP protein. It was observed that SIT showed the best value for OptimalAvgFE followed by COR, SWE and AMR. However, there was a difference of around 1.4 kcal/mol between SIT and COR. This difference was considerably small as compared to the difference of 7.8 and 8.8 kcal/mol between SIT and SWE, SIT and AMR, respectively. These free energy values suggests that SIT and COR showed comparatively better binding than SWE and AMR.

Fig 5. Free energy of binding of phytochemicals.

Fig 5

Optimal average of free energy of binding between the phytochemicals SWE (black), AMR (red), SIT (green) and COR (blue) and RdRP protein.

The residue-wise contribution in free energy of binding between the phytochemicals and RdRP was calculated for 26 residues (Fig 6). PLIP software was used to find out the residues that were involved in either hydrophilic or hydrophobic interactions with the phytochemicals [65]. It was observed that a total of twenty-six residues namely, ASP 452, TYR 455, LYS 500, SER 549, ALA 550, ALA 553, ARG 555, GLY 616, ASP 618, LYS 621, CYS 622, ASP 623, ARG 624, SER 682, GLY 683, ASP 684, SER 759, ASP 760, ASP 761, LYS 798, TRP 800, GLU 811, CYS 813, SER 814 and ARG 836, were common to all the four phytochemicals. Most of these residues belonged to either of the seven conserved motifs. Five of the six residues from the two catalytic sites SDD (SER 759, ASP 760, ASP 761) from motif C and CSQ (CYS 813, SER 814, GLN 815) from motif E were observed to be involved in forming interactions with the phytochemicals. SER 549, ALA 550, ALA 553 and ARG 555 belonged to the ligand-binding motif F. LYS 500, SER 682, GLY 683, and ASP 684 are known to bind to the RNA template and are a part of the FD1 and FD2 subdomains and also belong to motifs G and B. GLY 616, ASP 618, LYS 621, CYS 622, ASP 623, and ARG 624 belong to motif A. ASP 452 (FD1), TYR 455 (FD1), LYS 798 (PD), TRP 800 (PD) and ARG 836 (TD) do not belong to any conserved motif but are a part of the three crucial subdomains. Fig 6A–6D shows the free energy contribution of these residues in binding to SWE, AMR, SIT and COR, respectively. A free energy value lower than zero indicates favorable binding. The two arginine residues from the ligand binding motif F, namely ARG 553 and ARG 555 were observed to show significantly better free energy of binding with all the phytochemicals in comparison to the rest of the residues. Most of the residues that were observed to form hydrogen bond or salt bridge interactions (Fig 4) with either of the four phytochemicals had considerably better free energy values. The best free energy contribution was by ARG 555 in binding to the SWE in comparison to all others. Comparatively, more number of residues were observed to bind favorably in case of SIT and COR than SWE and AMR. SER 682, GLY 683 and ARG 684 which belong to motif B and are known to be involved in binding to the RNA template showed favorable binding to SIT. Similarly, LYS 798, TRP 800 and GLU 811 from the PD subdomain and motif E showed the most favorable binding to the COR. Apart from ARG 553 and ARG 555, SER 549, ALA 550, LYS 551 from the ligand binding motif F were observed to be binding favorably to all the four phytochemicals.

Fig 6. Contribution in binding by interacting residues.

Fig 6

Residue-wise free energy contribution in binding between the ligands (A) SWE, (B) AMR, (C) SIT, and (D) COR and the RdRP protein.

Predominant RdRP residues in inhibitor binding

One of the earlier simulation studies reported by the authors had described the interacting residues of RdRP with nucleotide analogues [51]. Six nucleotide analogues were studied, namely, favipiravir, galidesivir, lamivudine, ribavirin, remdesivir and sofosbuvir. Fig 7 lists the common RdRP residues that were observed to be involved in interacting with the phytochemicals and these nucleoside analogues. It was observed that overall twenty-six and twenty RdRP residues were involved in binding to the phytochemicals and nucleoside analogues respectively. Among these, seventeen residues were observed to be common to both. The function-site interaction fingerprint method performed by Zhoa Z and Bourne PE, suggests the interaction with inhibitors by LYS 551, ARG 553, ASP 623, SER 682 and ASP 760 residues from the different conserved motifs of RdRP [30]. Similar interactions were observed in the experimental structure of remdesivir-bound RNA in complex with RdRP of SARS-CoV-2 [31]. In the present study, these six residues were obtained to be interacting with all the four phytochemicals. The free energy values also showed that these six residues showed favorable binding (Fig 6). ASP 760 which is a catalytic site residue was involved in formation of water mediated interactions with SWE and AMR. SER 682 formed hydrogen bonds and salt bridges with SIT. COR formed hydrogen bonds with ARG 553. Although, COR showed no significant interaction with ASP 760, it formed strong water-mediated hydrogen bond with its neighbouring catalytic site residue ASP 761. This suggests the importance of the two aspartate residues which have also been reported earlier by Aftab et al. [20]. Similarly, one of the earlier reported computational studies on remdesivir binding to RdRP suggests the role of SER 549, ARG 555, ASP 618 and LYS 798 [27]. ARG 555 and ASP 618 were observed to form stable hydrogen bond/salt bridge interactions with SWE, AMR and COR. However, SER 549 was observed to interact more with SIT as compared to the other three phytochemicals (Figs 4C and 6). LYS 798 was observed to form hydrogen bonding with SWE and COR. Virtual screening studies on small molecules that are non-nucleotide inhibitors, as are the phytochemicals, suggests the role of GLU 811 and the CSQ catalytic site in binding to the inhibitors [29]. SWE and COR were observed to form water mediated interactions with GLU 811 (Fig 4A and 4D). SER 814 from the CSQ catalytic site was also observed to form hydrogen bond/salt bridge interactions with SWE and COR. These observations suggest that the important RdRP residues known to be involved in its inhibition showed significant interactions with the phytochemicals.

Fig 7. Inhibitor binding RdRP residues.

Fig 7

Unique and common RdRP residues interacting with phytochemicals (PC) and nucleotide analogues (NA) observed through MD simulations.

Interacting moieties of phytochemicals

The four phytochemicals explored in this study consist of a withanolide derivative and glycosides. SWE is a xanthone glycoside known to have anti-viral properties [66]. AMR is a bitter secoiridoids glycoside, which possess anti-microbial properties [67]. SIT is a glycowithanolide known to have antineoplastic activity [68]. COR is a sulfur-containing clerodane diterpene glycoside, with known immunomodulatory properties [69]. The glucose moiety appeared to be the common functional group in each of these four phytochemcials. This moiety was flanked by either hydrophilic or hydrophobic functional groups. Fig 8 shows the snapshot of RdRP residues interacting with the phytochemicals. The glucose moieties have been shown in red circle. SWE has a hydroxyl-methoxyxanthone ring which was observed to interact with the postively charged amino acid arginine (Fig 8A). The other two glucopyranoside rings were observed to form strong water mediated interactions with negatively charged amino acids aspartate and glutamate. AMR has an iridoid and a trihydroxy-biphenyl-carboxylic acid moiety [67]. They were observed to form stable interactions with aspartate residues (Fig 8B). The glucose moieties in SIT and COR were observed to form water mediated interactions with charged amino acids, namely, arginine, lysine and aspartate (Fig 8C and 8D) [68, 69]. The free energy of binding values for these two phytochemicals suggests that the interaction of charged amino acids with the glucose moieties may be energetically more favourable. Hence, it may be inferred that these glycoside derivatives prove to be efficient binders when their interacting partners are hydrophilic and charged amino acids.

Fig 8. Phytochemical interaction partners.

Fig 8

Snapshots of RdRP residues forming hydrogen bonds (blue) and water mediated (cyan) interactions with (A) SWE, (B) AMR, (C) SIT and (D) COR. The red circle denotes the interacting glucose moieties of the phytochemicals.

Conclusion

The present study explains the capability of phytochemicals from Indian medicinal plants in forming stable interactions with the RdRP of the SARS-CoV-2. Previously, decoded mechanisms of pre-mature RNA termination by drugs indicate the role of dominant molecular motions in the finger and thumb subdomains of the RdRP. Similarly, the molecular dynamics simulations reported here, comprehend these molecular motions through PCA and distance calculations. The phytochemical-bound RdRP systems sampled closed conformations of the template entry site. Whereas, the ligand-free RdRP system pre-dominantly showed only open conformation for the same. Hydrogen bonding, salt bridge interactions and free energy calculations suggest favourable binding of sitoindoside IX, cordifolide A and swertiapuniside. However, cordifolide A with minimal difference in free energy of binding against sitoindoside IX was observed to form long lasting water mediated hydrogen bonds with the catalytic site aspartate residues. It may infer that it has more potential in strong binding to RdRP as compared to the remaining three phytochemicals. The key approach in designing a small molecular inhibitor lies in their prospects to form energetically favourable interactions within the drug-target. ARG 553, ARG 555, ASP 618, ASP 760, ASP 761, GLU 811, SER 814 were observed to participate in such interactions. Here, the interacting partners were the glycosidic moieties of these phytochemicals. Overall, the finding reported in this article proposes the phytochemicals as stable RdRP catalytic site binders, synergistic with the experimentally known drug-RdRP interactions.

Supporting information

S1 File

(DOCX)

Acknowledgments

The authors would also like to thank the National PARAM Supercomputing Facility (NPSF) and Bioinformatics Resources and Applications Facility (BRAF) for the computing infrastructure

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was funded by the Ministry of Electronics and Information Technology, Government of India, under the project, National Supercomputing Mission (NSM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Data obtained from https://covid19.who.int
  • 2.Wang H, Li X, Li T, Zhang S, Wang L, Wu X, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. European Journal of Clinical Microbiology & Infectious Diseases. 2020. April 24:1–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kristian G, Andersen AR, Lipkin I, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450–5. 10.1038/s41591-020-0820-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. Cell. 2020. May 14;181(4):914–21. 10.1016/j.cell.2020.04.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Nat Rev Drug Discov. 2020; 19: 149–150. 10.1038/d41573-020-00016-0 [DOI] [PubMed] [Google Scholar]
  • 6.Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020. May 1;10(5):766–88. 10.1016/j.apsb.2020.02.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Cherian SS, Agrawal M, Basu A, Abraham P, Gangakhedkar RR, Bhargava B. Perspectives for repurposing drugs for the coronavirus disease 2019. The Indian Journal of Medical Research. 2020. February;151(2–3):160. 10.4103/ijmr.IJMR_585_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Pawar AY. Combating Devastating COVID -19 by Drug Repurposing. Int J Antimicrob Agents. 2020. April 17:105984.[Epub ahead of print] 10.1016/j.ijantimicag.2020.105984 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Serafin MB, Bottega A, Foletto VS, da Rosa TF, Hörner A, Hörner R. Drug repositioning is an alternative for the treatment of coronavirus COVID-19. Int J Antimicrob Agents. 2020. April 9:105969.[Epub ahead of print] 10.1016/j.ijantimicag.2020.105969 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sci. 2020. April 9;252:117652.[Epub ahead of print] 10.1016/j.lfs.2020.117652 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wang C, Liu Z, Chen Z, Huang X, Xu M, He T, et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol. 2020. March 13.[Epub ahead of print] 10.1002/jmv.25762 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Yadav PD, Potdar VA, Choudhary ML, Nyayanit DA, Agrawal M, Jadhav SM, et al. Full-genome sequences of the first two SARS-CoV-2 viruses from India. Indian J Med Res. 2020. March 27.[Epub ahead of print] 10.4103/ijmr.IJMR_663_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bauer DC, Tay AP, Wilson LOW, Reti D, Hosking C, McAuley AJ, et al. Supporting pandemic response using genomics and bioinformatics: a case study on the emergent SARS-CoV-2 outbreak. Transbound Emerg Dis. 2020. April 19. [Epub ahead of print] 10.1111/tbed.13588 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A. 2020. April 8;pii: 202004999. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Stefanelli P, Faggioni G, Lo Presti A, Fiore S, Marchi A, Benedetti E, et al. Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe. Euro Surveill. 2020. April;25(13). 10.2807/1560-7917.ES.2020.25.13.2000305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Li C, Yang Y, Ren L. Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species. Infect Genet Evol. 2020. March 10;82:104285. [Epub ahead of print] 10.1016/j.meegid.2020.104285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. Author Correction: A new coronavirus associated with human respiratory disease in China. Nature. 2020. April;580(7803):E7. 10.1038/s41586-020-2202-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Prajapat M, Sarma P, Shekhar N, Prakash A, Avti P, Bhattacharyya A, et al. Update on the target structures of SARS-CoV-2: A systematic review. Indian J Pharmacol. 2020. Mar-Apr;52(2):142–149. 10.4103/ijp.IJP_338_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Srinivasan S, Cui H, Gao Z, Liu M, Lu S, Mkandawire W, et al. Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins. Viruses. 2020. March 25;12(4):360. 10.3390/v12040360 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Aftab SO, Ghouri MZ, Masood MU, Haider Z, Khan Z, Ahmad A, et al. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med. 2020. July 7;18(1):275. 10.1186/s12967-020-02439-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wang Y, Anirudhan V, Du R, Cui Q, Rong L. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. J Med Virol. 2020. July 7.[Epub ahead of print] 10.1002/jmv.26264 [DOI] [PubMed] [Google Scholar]
  • 22.Chien M, Anderson TK, Jockusch S, Tao C, Li X, Kumar S, et al. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. J Proteome Res. 2020. July 21. [Epub ahead of print] 10.1021/acs.jproteome.0c00392 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses. 2019. April 4;11(4):326. 10.3390/v11040326 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018. May;153:85–94. 10.1016/j.antiviral.2018.03.003 [DOI] [PubMed] [Google Scholar]
  • 25.Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn. 2020. May 6:1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020. April 29;12(541):eabb5883. 10.1126/scitranslmed.abb5883 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zhang L, Zhou R. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase. J Phys Chem B. 2020. August 13;124(32):6955–6962. 10.1021/acs.jpcb.0c04198 [DOI] [PubMed] [Google Scholar]
  • 28.Koulgi S, Jani V, Uppuladinne V N M, Sonavane U and Joshi R. Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2. RSC Adv., 2020, 10, 26792–26803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ahmad J, Ikram S, Ahmad F, Rehman IU, Mushtaq M. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp)—A drug repurposing study. Heliyon. 2020. July 23;6(7):e04502. 10.1016/j.heliyon.2020.e04502 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zhao Z, Bourne PE. Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug Discovery. J Proteome Res. 2020. September 29.[Epub ahead of print] 10.1021/acs.jproteome.0c00623 [DOI] [PubMed] [Google Scholar]
  • 31.Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020. June 26;368(6498):1499–1504. 10.1126/science.abc1560 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Parasuraman S, Thing GS, Dhanaraj SA. Polyherbal formulation: Concept of ayurveda. Pharmacogn Rev. 2014. July;8(16):73–80. 10.4103/0973-7847.134229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Salehi B, Ata A, V Anil Kumar N, Sharopov F, Ramírez-Alarcón K, Ruiz-Ortega A, et al. Antidiabetic Potential of Medicinal Plants and Their Active Components. Biomolecules. 2019. September 30;9(10):551. 10.3390/biom9100551 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wu X, Zhang H, Salmani JM, Fu R, Chen B. Advances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumors. Onco Targets Ther. 2016. May 17;9:2935–43. 10.2147/OTT.S105586 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Vimalanathan S., Ignacimuthu S. & Hudson J.B.. Medicinal plants of Tamil Nadu (Southern India) are a rich source of antiviral activities, Pharmaceutical Biology, 2009; 47:5, 422–429. [Google Scholar]
  • 36.Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020. August;10(4):313–319. 10.1016/j.jpha.2020.03.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Mani JS, Johnson JB, Steel JC, Broszczak DA, Neilsen PM, Walsh KB, et al. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res. 2020. July 15;284:197989. 10.1016/j.virusres.2020.197989 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Vardhan S, Sahoo SK. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. Comput Biol Med. 2020. September;124:103936. 10.1016/j.compbiomed.2020.103936 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Parida PK, Paul D, Chakravorty D. The natural way forward: Molecular dynamics simulation analysis of phytochemicals from Indian medicinal plants as potential inhibitors of SARS-CoV-2 targets. Phytother Res. 2020. September 24; 10.1002/ptr.6868 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Shree P, Mishra P, Selvaraj C, Singh SK, Chaube R, Garg N, et al. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants—Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi)—a molecular docking study. J Biomol Struct Dyn. 2020. August 27:1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Rakib A, Paul A, Chy MNU, Sami SA, Baral SK, Majumder M, et al. Biochemical and Computational Approach of Selected Phytocompounds from Tinospora crispa in the Management of COVID-19. Molecules. 2020. August 28;25(17):3936. 10.3390/molecules25173936 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Vijayakumar BG, Ramesh D, Joji A, Jayachandra Prakasan J, Kannan T. In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2. Eur J Pharmacol. 2020. November 5;886:173448. 10.1016/j.ejphar.2020.173448 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020. May 15;368(6492):779–782. 10.1126/science.abb7498 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019. January 8;47(D1):D1102–D1109. 10.1093/nar/gky1033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Caffeine. SciFinder. CAS, n.d. https://scifinder-cas-org.proxy.queensu.ca/ (accessed 2020-03-28). IR spectral data obtained from Wiley Subscription Services. (CAS RN: 58-08-2).
  • 46.O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011. October 7;3:33. 10.1186/1758-2946-3-33 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004. October;25(13):1605–12. 10.1002/jcc.20084 [DOI] [PubMed] [Google Scholar]
  • 48.Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J Chem Theory Comput. 2015. August 11;11(8):3696–713. 10.1021/acs.jctc.5b00255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004. July 15;25(9):1157–74. Erratum in: J Comput Chem. 2005 Jan 15;26(1):114. 10.1002/jcc.20035 [DOI] [PubMed] [Google Scholar]
  • 50.Allen WJ, Balius TE, Mukherjee S, Brozell SR, Moustakas DT, Lang PT, et al. DOCK 6: Impact of new features and current docking performance. J Comput Chem. 2015. June 5;36(15):1132–56. 10.1002/jcc.23905 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Koulgi S, Jani V, V N MU, Sonavane U, Joshi R. Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2. J Biomol Struct Dyn. 2021. March 8:1–15. 10.1080/07391102.2021.1894985 [DOI] [PubMed] [Google Scholar]
  • 52.Yang H, Lou C, Sun L, Li J, Cai Y, Wang Z, et al. admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. Bioinformatics. 2019. March 15;35(6):1067–1069. 10.1093/bioinformatics/bty707 [DOI] [PubMed] [Google Scholar]
  • 53.Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017. March 3;7:42717. 10.1038/srep42717 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Case D. A., Betz R. M., Cerutti D. S., Cheatham T. E. III, Darden T. A., Duke R. E., et al., AMBER 2016, University of California, San Francisco. 2016. [Google Scholar]
  • 55.Peters MB, Yang Y, Wang B, Füsti-Molnár L, Weaver MN, Merz KM Jr. Structural Survey of Zinc Containing Proteins and the Development of the Zinc AMBER Force Field (ZAFF). J Chem Theory Comput. 2010. September 14;6(9):2935–2947. 10.1021/ct1002626 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Wang J, Wang W, Kollman PA, Case DA. Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model. 2006. October;25(2):247–60. 10.1016/j.jmgm.2005.12.005 [DOI] [PubMed] [Google Scholar]
  • 57.Roe DR, Cheatham TE 3rd. Parallelization of CPPTRAJ enables large scale analysis of molecular dynamics trajectory data. J Comput Chem. 2018. September 30;39(25):2110–2117. 10.1002/jcc.25382 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Bakan A, Meireles LM, Bahar I. ProDy: protein dynamics inferred from theory and experiments. Bioinformatics. 2011. June 1;27(11):1575–7. 10.1093/bioinformatics/btr168 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996. February;14(1):33–8, 27–8. 10.1016/0263-7855(96)00018-5 [DOI] [PubMed] [Google Scholar]
  • 60.https://getcontacts.github.io/
  • 61.Miller BR 3rd, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. J Chem Theory Comput. 2012. September 11;8(9):3314–21. 10.1021/ct300418h [DOI] [PubMed] [Google Scholar]
  • 62.Appleby TC, Perry JK, Murakami E, Barauskas O, Feng J, Cho A, et al. Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. Science. 2015. February 13;347(6223):771–5. 10.1126/science.1259210 [DOI] [PubMed] [Google Scholar]
  • 63.Moustafa IM, Shen H, Morton B, Colina CM, Cameron CE. Molecular dynamics simulations of viral RNA polymerases link conserved and correlated motions of functional elements to fidelity. J Mol Biol. 2011. July 1;410(1):159–81. 10.1016/j.jmb.2011.04.078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Thompson AA, Albertini RA, Peersen OB. Stabilization of poliovirus polymerase by NTP binding and fingers-thumb interactions. J Mol Biol. 2007. March 9;366(5):1459–74. 10.1016/j.jmb.2006.11.070 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res. 2015. July 1;43(W1):W443–7. 10.1093/nar/gkv315 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Kumar V, Van Staden J. A Review of Swertia chirayita (Gentianaceae) as a Traditional Medicinal Plant. Front Pharmacol. 2016. January 12;6:308. 10.3389/fphar.2015.00308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Shukla S, Bafna K, Sundar D, Thorat SS. The bitter barricading of prostaglandin biosynthesis pathway: understanding the molecular mechanism of selective cyclooxygenase-2 inhibition by amarogentin, a secoiridoid glycoside from Swertia chirayita. PLoS One. 2014. March 6;9(6):e90637. 10.1371/journal.pone.0090637 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Dar PA, Singh LR, Kamal MA, Dar TA. Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component. Curr Pharm Des. 2016;22(5):535–40. 10.2174/1381612822666151125001751 [DOI] [PubMed] [Google Scholar]
  • 69.Pan L, Terrazas C, Lezama-Davila CM, Rege N, Gallucci JC, Satoskar AR, et al. Cordifolide A, a sulfur-containing clerodane diterpene glycoside from Tinospora cordifolia. Org Lett. 2012. April 20;14(8):2118–21. 10.1021/ol300657h [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Chandrabose Selvaraj

30 Mar 2021

PONE-D-20-38144

Molecular insights into the inhibitory effect of phytochemicals on RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2

PLOS ONE

Dear Dr. Joshi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 14 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Chandrabose Selvaraj, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

[The authors would like to acknowledge the National Supercomputing Mission for providing financial support for this work.]

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

 [The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.]

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors performed in silico analyses to study the molecular analyses and the inhibitory effect of phytochemicals on RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2. The article is interested however following points will help to improve the article.

1- The title should be more attractive.

2- Abstract has some confused statements. Please rewrite.

3- Discussion section is poorly drafted.

4- There are numerous typos and linguistics errors.

5- Figures are poorly drafted. Please improve.

6- Conclusion section is too long and a big chunk seems to be copied from Abstract. Please re write

Reviewer #2: The problem with computational methods is that they always show results, even when the starting points are useless. This is the reason why one should be really careful about the setup of such computational methods. The current study mixed several approaches to earn the publication, however, they failed to enhance the more consistent general research approach or a more obvious integration of computational techniques, to reach to a suitable conclusion. A validation of their computational approach is needed in this research. Ultimately, I do not think that the manuscript is suitable to process further.

Reviewer #3: 1) Overall the language needs to be corrected as I could see non-scientific way of explaining all through out the manuscript. For example "The availability of immense structural knowledge on one of the hottest drug target of SARS-CoV-2,...."

2) Also the manuscript requires significant re-writing as the sentences go on like a paragraph and hard to get along with the flow of the manuscript.

3) The introduction is exhaustive and should be reduced to maximum of two pages with key elements of the study.

4) I am not sure why the authors have discussed few results and methodology in the introduction section.

5) The authors mention that "The availability of immense structural knowledge on one of the hottest drug target of SARS-CoV-2, RdRP and in-silico techniques like, molecular docking and simulations would enable the designing of inhibitors based on

screening of phytochemicals from medicinal plants specific to treating respiratory ailments" these phytochemicals from 12 medicinal plants evaluated in this current study were proven to treat respiratory ailments. But the authors fail to cite the references. So it is advisable to include the references for all 12 medicinal plants showing their potential relevance against respiratory diseases.

6) Were the phytochemicals from these 12 medicinal plants reported after GC-MS analysis, if so cite the refence for that.

7) The authors need to mention, how many phytochemicals were extracted out of these 12 medicinal plants ?

8) Did the authors check ADMET property of these phytochemicals ? if so furnish the ADMET data.

9) Bond length information should be listed as table for at least top 10 interactions.

10) Discussion has to be more directed towards the chemical nature of the compound and it's interacting partners, this will be more interesting rather than focusing on the amino acid residues at the active site. Hence, the authors are encouraged to focus more on the chemical entities of the phytochemicals and discuss about it's medicinal property.

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 May 13;16(5):e0251801. doi: 10.1371/journal.pone.0251801.r002

Author response to Decision Letter 0


26 Apr 2021

The authors would like to thank the editor and the reviewers for their valuable suggestions and comments. They have helped in enhancing the scientific merit and readability of the manuscript. The authors sincerely hope that the revised manuscript would satisfy the concerns raised by the reviewers. A detailed response to every comment/suggestion has been given (highlighted in yellow). The additions made in the revised manuscript have been highlighted in grey.

Reviewer #1: Authors performed in silico analyses to study the molecular analyses and the inhibitory effect of phytochemicals on RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2. The article is interested however following points will help to improve the article.

1-The title should be more attractive.

Response: The authors have modified the title as per reviewer’s suggestion. The new title has been given below.

Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2

2-Abstract has some confused statements. Please rewrite.

Response: The abstract has been re-written to avoid any confused statements. The changes made in the abstract of the revised manuscript have been highlighted.

3-Discussion section is poorly drafted.

Response: The discussion section has been revisited and re-drafted for better understanding of the results. The changes made have been highlighted in yellow in the revised manuscript.

4-There are numerous typos and linguistics errors.

Response: The entire manuscript has been revised to rectify the grammatical errors.

5-Figures are poorly drafted. Please improve.

Response: As per the reviewer’s suggestion, few of the figures have been redrafted for better understanding of the results. The old figures 1, 4, 5, 6, and 7 have been modified in the revised manuscript. The revised manuscript now contains eight figures. The 2D-representations of the four phytochemicals in the old figure 1 has now been shifted to supplementary figure S2. The revised figure 1 has been given below.

Fig 1. Structure of RdRP of SARS-CoV-2. The different (A) subdomains and (B) the seven conserved motifs in RdRP of SARS-CoV-2 represented through color codes.

The sub-figure A of the old figures 4-7 have been removed as they were observed to be repetitive with the sub-figure B. Revised figure 4 now shows the contact frequency of the hydrogen bond and water mediated interactions for (A) SWE, (B) AMR, (C) SIT and (D) COR. The revised figure 4 has been given below.

Fig 4. Stable interactions formed by the phytochemicals. Contact frequency of the hydrogen-bond and water mediated interactions between the RdRP residues and (A) SWE, (B) AMR, (C) SIT and (D) COR.

The sub-figure C of the old figures 4-7 have been included as a new Figure 8 in the revised manuscript. The new figure 8 talks about the functional moieties of the phytochemicals interacting with different amino acids of RdRP. The new figure 8 from the revised manuscript has been given below. A paragraph describing this figure has also been included (as per one of the reviewer’s suggestions).

Fig 8. Phytochemical interaction partners. Snapshots of RdRP residues forming hydrogen bonds (blue) and water mediated (cyan) interactions with (A) SWE, (B) AMR, (C) SIT and (D) COR. The red circle denotes the interacting glucose moieties of the phytochemicals.

The following paragraph has been included in the “Results and Discussion”

Interacting moieties of phytochemicals

The four phytochemicals explored in this study consist of a withanolide derivative and glycosides. SWE is a xanthone glycoside known to have anti-viral properties [66]. AMR is a bitter secoiridoids glycoside, which possess anti-microbial properties [67]. SIT is a glycowithanolide known to have antineoplastic activity [68]. COR is a sulfur-containing clerodane diterpene glycoside, with known immunomodulatory properties [69]. The glucose moiety appeared to be the common functional group in each of these four phytochemcials. This moiety was flanked by either hydrophilic or hydrophobic functional groups. Fig 8 shows the snapshot of RdRP residues interacting with the phytochemicals. The glucose moieties have been shown in red circle. SWE has a hydroxyl-methoxyxanthone ring which was observed to interact with the postively charged amino acid arginine (Fig 8 A). The other two glucopyranoside rings were observed to form strong water mediated interactions with negatively charged amino acids aspartate and glutamate. AMR has an iridoid and a trihydroxy-biphenyl-carboxylic acid moiety [67]. They were observed to form stable interactions with aspartate residues (Fig 8 B). The glucose moieties in SIT and COR were observed to form water mediated interactions with charged amino acids, namely, arginine, lysine and aspartate (Fig 8 C and D) [68, 69]. The free energy of binding values for these two phytochemicals suggests that the interaction of charged amino acids with the glucose moieties may be energetically more favourable. Hence, it may be inferred that these glycoside derivatives prove to be efficient binders when their interacting partners are hydrophilic and charged amino acids.

6-Conclusion section is too long and a big chunk seems to be copied from Abstract. Please re write

Response: The “Conclusion” section in the revised manuscript has been re-drafted and there are no repetitions.

Reviewer #2: The problem with computational methods is that they always show results, even when the starting points are useless. This is the reason why one should be really careful about the setup of such computational methods. The current study mixed several approaches to earn the publication, however, they failed to enhance the more consistent general research approach or a more obvious integration of computational techniques, to reach to a suitable conclusion. A validation of their computational approach is needed in this research. Ultimately, I do not think that the manuscript is suitable to process further.

Response: The authors agree to the fact that the results need the validation through experiments. However, currently the observations have been supported by the few of the literature reports which have used similar computational approaches.

Reviewer #3:

1)Overall the language needs to be corrected as I could see non-scientific way of explaining all through out the manuscript. For example "The availability of immense structural knowledge on one of the hottest drug target of SARS-CoV-2,...."

Response: The manuscript has been revisited and revised according to the reviewer’s suggestions.

2)Also the manuscript requires significant re-writing as the sentences go on like a paragraph and hard to get along with the flow of the manuscript.

Response: The manuscript has been re-written and the sentences have been shortened or split in order to improve the readability.

3)The introduction is exhaustive and should be reduced to maximum of two pages with key elements of the study.

Response: The “Introduction” section has been reduced considerably in the revised manuscript.

4)I am not sure why the authors have discussed few results and methodology in the introduction section.

Response: The “Introduction” section has been reduced considerably in the revised manuscript. The sentences explaining the results and methodology have now been removed from the “Introduction” of the revised manuscript.

5) The authors mention that "The availability of immense structural knowledge on one of the hottest drug target of SARS-CoV-2, RdRP and in-silico techniques like, molecular docking and simulations would enable the designing of inhibitors based on

screening of phytochemicals from medicinal plants specific to treating respiratory ailments" these phytochemicals from 12 medicinal plants evaluated in this current study were proven to treat respiratory ailments. But the authors fail to cite the references. So it is advisable to include the references for all 12 medicinal plants showing their potential relevance against respiratory diseases.

Response: The references for all twelve medicinal plants included in this study have been added and have also been cited accordingly. The references have been mentioned along with the supplementary Figure S1. The revised supplementary figure S1 has been given below.

S1 Fig. Methodology. Protocol followed for creation of the phytochemical dataset with the list of the Indian medicinal plant sources.

References numbered as superscripts beside the scientific name of the plants:

1.Saini A, Sharma S, Chhibber S. Induction of resistance to respiratory tract infection with Klebsiella pneumoniae in mice fed on a diet supplemented with tulsi (Ocimum sanctum) and clove (Syzgium aromaticum) oils. J Microbiol Immunol Infect. 2009 Apr;42(2):107-13. PMID: 19597641.

2.Cohen MM. Tulsi - Ocimum sanctum: A herb for all reasons. J Ayurveda Integr Med. 2014 Oct-Dec;5(4):251-9. doi: 10.4103/0975-9476.146554. PMID: 25624701; PMCID: PMC4296439.

3.Lee JW, Ryu HW, Park SY, Park HA, Kwon OK, Yuk HJ, Shrestha KK, Park M, Kim JH, Lee S, Oh SR, Ahn KS. Protective effects of neem (Azadirachta indica A. Juss.) leaf extract against cigarette smoke- and lipopolysaccharide-induced pulmonary inflammation. Int J Mol Med. 2017 Dec;40(6):1932-1940. doi: 10.3892/ijmm.2017.3178. Epub 2017 Oct 10. PMID: 29039495.

4.Jose Francisco Islas, Ezeiza Acosta, Zuca G-Buentello, Juan Luis Delgado-Gallegos, María Guadalupe Moreno-Treviño, Bruno Escalante, Jorge E. Moreno-Cuevas. An overview of Neem (Azadirachta indica) and its potential impact on health. Journal of Functional Foods, Volume 74, 2020, 104171, ISSN 1756-4646,doi: 10.1016/j.jff.2020.104171.\\

5.Kumari M, Ashok BK, Ravishankar B, Pandya TN, Acharya R. Anti-inflammatory activity of two varieties of Pippali (Piper longum Linn.). Ayu. 2012 Apr;33(2):307-10. doi: 10.4103/0974-8520.105258. PMID: 23559810; PMCID: PMC3611634.

6.Saha S, Ghosh S. Tinospora cordifolia: One plant, many roles. Anc Sci Life. 2012 Apr;31(4):151-9. doi: 10.4103/0257-7941.107344. PMID: 23661861; PMCID: PMC3644751.

7.Sharma P, Dwivedee BP, Bisht D, Dash AK, Kumar D. The chemical constituents and diverse pharmacological importance of Tinospora cordifolia. Heliyon. 2019 Sep 12;5(9):e02437. doi: 10.1016/j.heliyon.2019.e02437. PMID: 31701036; PMCID: PMC6827274.

8.Antul, K., P. Amandeep, S. Gurwinder, and C. Anuj. “Review on Pharmacological Profile of Medicinal Vine: Tinospora Cordifolia”. Current Journal of Applied Science and Technology, Vol. 35, no. 5, June 2019, pp. 1-11, doi:10.9734/cjast/2019/v35i530196.

9.Kumar V, Van Staden J. A Review of Swertia chirayita (Gentianaceae) as a Traditional Medicinal Plant. Front Pharmacol. 2016 Jan 12;6:308. doi: 10.3389/fphar.2015.00308. PMID: 26793105; PMCID: PMC4709473.

10.Dey P, Singh J, Suluvoy JK, Dilip KJ, Nayak J. Utilization of Swertia chirayita Plant Extracts for Management of Diabetes and Associated Disorders: Present Status, Future Prospects and Limitations. Nat Prod Bioprospect. 2020 Dec;10(6):431-443. doi: 10.1007/s13659-020-00277-7. Epub 2020 Oct 28. PMID: 33118125; PMCID: PMC7648839.

11.Koul A, Bala S, Yasmeen, Arora N. Aloe vera affects changes induced in pulmonary tissue of mice caused by cigarette smoke inhalation. Environ Toxicol. 2015 Sep;30(9):999-1013. doi: 10.1002/tox.21973. Epub 2014 Feb 24. PMID: 24615921.

12.Zayas LE, Wisniewski AM, Cadzow RB, Tumiel-Berhalter LM. Knowledge and use of ethnomedical treatments for asthma among Puerto Ricans in an urban community. Ann Fam Med. 2011 Jan-Feb;9(1):50-6. doi: 10.1370/afm.1200. PMID: 21242561; PMCID: PMC3022046.

13.Shridhar Dwivedi, Terminalia arjuna Wight & Arn.—A useful drug for cardiovascular disorders, Journal of Ethnopharmacology, Volume 114, Issue 2, 2007, Pages 114-129, ISSN 0378-8741, https://doi.org/10.1016/j.jep.2007.08.003.

14.Townsend EA, Siviski ME, Zhang Y, Xu C, Hoonjan B, Emala CW. Effects of ginger and its constituents on airway smooth muscle relaxation and calcium regulation. Am J Respir Cell Mol Biol. 2013 Feb;48(2):157-63. doi: 10.1165/rcmb.2012-0231OC. Epub 2012 Oct 11. PMID: 23065130; PMCID: PMC3604064.

15.Anh NH, Kim SJ, Long NP, Min JE, Yoon YC, Lee EG, Kim M, Kim TJ, Yang YY, Son EY, Yoon SJ, Diem NC, Kim HM, Kwon SW. Ginger on Human Health: A Comprehensive Systematic Review of 109 Randomized Controlled Trials. Nutrients. 2020 Jan 6;12(1):157. doi: 10.3390/nu12010157. PMID: 31935866; PMCID: PMC7019938.

16.Choudhary B, Shetty A, Langade DG. Efficacy of Ashwagandha (Withania somnifera [L.] Dunal) in improving cardiorespiratory endurance in healthy athletic adults. Ayu. 2015 Jan-Mar;36(1):63-8. doi: 10.4103/0974-8520.169002. PMID: 26730141; PMCID: PMC4687242.

17.Rahmani AH, Alsahli MA, Aly SM, Khan MA, Aldebasi YH. Role of Curcumin in Disease Prevention and Treatment. Adv Biomed Res. 2018 Feb 28;7:38. doi: 10.4103/abr.abr_147_16. PMID: 29629341; PMCID: PMC5852989.

18.Samareh Fekri M, Poursalehi HR, Sharififar F, Mandegary A, Rostamzadeh F, Mahmoodi R. The effects of methanolic extract of Glycyrrhiza glabra on the prevention and treatment of bleomycin-induced pulmonary fibrosis in rat: experimental study. Drug Chem Toxicol. 2019 May 9:1-7. doi: 10.1080/01480545.2019.1606232. Epub ahead of print. PMID: 31072167.

19.Wang L, Yang R, Yuan B, Liu Y, Liu C. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharm Sin B. 2015 Jul;5(4):310-5. doi: 10.1016/j.apsb.2015.05.005. Epub 2015 Jun 17. PMID: 26579460; PMCID: PMC4629407.

20.Okhuarobo A, Falodun JE, Erharuyi O, Imieje V, Falodun A, Langer P. Harnessing the medicinal properties of Andrographis paniculata for diseases and beyond: a review of its phytochemistry and pharmacology. Asian Pac J Trop Dis. 2014 Jun;4(3):213–22. doi: 10.1016/S2222-1808(14)60509-0. PMCID: PMC4032030.

5)Were the phytochemicals from these 12 medicinal plants reported after GC-MS analysis, if so cite the refence for that.

Response: These phytochemicals were selected based on their availability in PubChem and CAS databases. The PubChem CIDs and CAS IDs have been referred accordingly. No experiments were performed for selection of these phytochemicals.

6)The authors need to mention, how many phytochemicals were extracted out of these 12 medicinal plants ?

Response: A total of 150 phytochemicals were selected out of the 12 medicinal plants. This information has been included in the revised manuscript.

7)Did the authors check ADMET property of these phytochemicals ? if so furnish the ADMET data.

Response: The authors have checked the ADMET property for the top-ranked four phytochemicals, namely, swertiapuniside, cordifolide A, sitoindoside IX and amarogentin. A supplementary table S1 with a short paragraph explaining the ADMET properties has now been added in the supplementary data. The supplementary table 1 along with the explanation included in the revised supplementary data has been given below.

S1 Table. ADMET properties. ADMET properties of the four phytochemicals.

    ABSORPTION DISTRIBUTION METABOLISM TOXICITY

Medicinal Plant (Source) Phytochemical Name GI WS SP

(Log Kp) BBB Crossing Subcellular Localization P-gly sub hERG inb CYP1A2 inb CYP2C19 inb

A*CYP2D6 inb CYP3A4 inb CAR

Swertia chirayita Swertiapuniside +  -1.64 -11.04 - Mitochondria + + - - - - -

Amarogentin + -2.97 -8.16 - Mitochondria - - - - - - -

Withania somnifera Sitoindoside IX +  -3.80 -8.97 + Mitochondria + + - - - - -

Tinospora cordifolia Cordifolide A - -3.542 -9.7 - Mitochondria + + - - - - -

The gastrointestinal absorption (GI), water solubility (WS) and skin permeation (SP) explains the absorption properties. Cordifolide A was observed to show low GI absorption, whereas, the remaining three showed favourable values for the same. The other two parameters showed allowed values for all the four phytochemicals. The blood-brain-barrier (BBB) crossing, subcellular localization and P-glycoprotein substrate (P-gly sub) parameters denote the distribution properties. All the phytochemicals were predicted to have the subcellular localization in the mitochondria. Except for amarogentin, all were predicted to serve as the P-glycoprotein substrate. Human ether-a-go-go Related Gene (hERG), cytochrome 1A2 (CYP1A2), cytochrome 2C19 (CYP2C19), cytochrome

2D6 (CYP2D6) and cytochrome 3A4 (CYP3A4) inhibitory property was calculated to understand the metabolism of the phytochemicals.Neither of them were predicted to be CYP inhibitors nor possessing toxic properties.

8)Bond length information should be listed as table for at least top 10 interactions.

Response: The bond length information for the hydrogen bonds formed between the phytochemicals and the residues of RdRP has been now included as supplementary table S2. The supplementary table S2 has been given below.

S2 Table. Bond distance of hydrogen bonds. The average bond distance for the hydrogen bond formed between RdRP residues and SWE, AMR, SIT and COR

RdRP Residue Hydrogen Bond Length (Å)

Swertiapuniside (SWE)

ASP 760 (C) 2.99

ASP 761 (C) 2.84

SER 759 (C) 2.85

LYS 551 (F) 3.5

ASP 618 (A) 3.28

ARG 555 (F) 3.4

GLU 811 (E) 2.81

SER 814 (E) 2.98

ARG 553 (F) 2.65

LYS 798 (PD) 2.88

Amarogentin (AMR)

LYS 621 (A) 2.99

ARG 553 (F) 3.45

ASP 452 (FD1) 2.66

ARG 555 (F) 3.3

ASP 618 (A) 3.22

ASP 760 (C) 3.38

Sitoindoside IX (SIT)

ARG 555 (F) 2.82

ASP 684 (B) 2.63

SER 682 (B) 2.67

ALA 550 (F) 2.95

SER 549 (F) 2.71

GLY 683 (B) 2.8

ALA 558 (FD1) 3.13

Cordifolide A (COR)

TRP 800 (PD) 3.09

LYS 798 (PD) 2.42

HIE 810 (PD) 2.3

ASP 618 (A) 3.21

SER 814 (E) 2.84

GLU 811 (E) 2.99

ARG 555 (F) 3.4

ASP 761 (C) 2.79

GLY 616 (A) 2.82

ARG 553 (F) 3.17

9)Discussion has to be more directed towards the chemical nature of the compound and it's interacting partners, this will be more interesting rather than focusing on the amino acid residues at the active site. Hence, the authors are encouraged to focus more on the chemical entities of the phytochemicals and discuss about it's medicinal property.

Response: The authors have included a new sub-section “Interacting moieties of phytochemicals” in the “Results and Discussion”. This section talks about the chemical moieties of the phytochemicals that were observed to interact with the different residues of RdRP. The newly included sub-section is as below.

Interacting moieties of phytochemicals

The four phytochemicals explored in this study consist of a withanolide derivative and glycosides. SWE is a xanthone glycoside known to have anti-viral properties [66]. AMR is a bitter secoiridoids glycoside, which possess anti-microbial properties [67]. SIT is a glycowithanolide known to have antineoplastic activity [68]. COR is a sulfur-containing clerodane diterpene glycoside, with known immunomodulatory properties [69]. The glucose moiety appeared to be the common functional group in each of these four phytochemcials. This moiety was flanked by either hydrophilic or hydrophobic functional groups. Fig 8 shows the snapshot of RdRP residues interacting with the phytochemicals. The glucose moieties have been shown in red circle. SWE has a hydroxyl-methoxyxanthone ring which was observed to interact with the postively charged amino acid arginine (Fig 8 A). The other two glucopyranoside rings were observed to form strong water mediated interactions with negatively charged amino acids aspartate and glutamate. AMR has an iridoid and a trihydroxy-biphenyl-carboxylic acid moiety [67]. They were observed to form stable interactions with aspartate residues (Fig 8 B). The glucose moieties in SIT and COR were observed to form water mediated interactions with charged amino acids, namely, arginine, lysine and aspartate (Fig 8 C and D) [68, 69]. The free energy of binding values for these two phytochemicals suggests that the interaction of charged amino acids with the glucose moieties may be energetically more favourable. Hence, it may be inferred that these glycoside derivatives prove to be efficient binders when their interacting partners are hydrophilic and charged amino acids.

A new figure, Figure 8 depicting the interacting residues with the glucose moieties has been included in the revised manuscript. The new figure 8 has been given below.

Fig 8. Phytochemical interaction partners. Snapshots of RdRP residues forming hydrogen bonds (blue) and water mediated (cyan) interactions with (A) SWE, (B) AMR, (C) SIT and (D) COR. The red circle denotes the interacting glucose moieties of the phytochemicals.

Attachment

Submitted filename: Response_to_reviewers_PlosOne_22April2021.docx

Decision Letter 1

Chandrabose Selvaraj

4 May 2021

Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2

PONE-D-20-38144R1

Dear Dr. Joshi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Chandrabose Selvaraj, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Accepted

nice efforts by the authors and also address all the questions effectively to meet the criteria of journal.

Reviewer #2: (No Response)

Reviewer #3: (No Response)

Acceptance letter

Chandrabose Selvaraj

6 May 2021

PONE-D-20-38144R1

Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2

Dear Dr. Joshi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Chandrabose Selvaraj

Academic Editor

PLOS ONE


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES